Kaminsky Vjacheslav, Chernyshov Viktor, Grynevych Oleksandr, Benyuk Vasil, Kornatskaya Alla, Shalko Miroslava, Usevich Igor, Revenko Oleg, Shepetko Maxim, Solomakha Ludmila
Shupyk National Medical Academy for Post-graduate Education, Kyiv, Ukraine.
State Institution "Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine", Kyiv; Ukraine.
Pol Merkur Lekarski. 2017 Mar 21;42(249):110-115.
Reporting of clinical trials results for Proteflazid® in the drug formulation suppositories and vaginal swabs soaked in the solution of the drug to the local immunity of the female reproductive tract.
The aim of study was to examine the state of local immunity in the reproductive tract of women with sexually transmitted diseases caused by human papillomavirus, herpes viruses (Type 1, 2) and mixed infection (herpes viruses + chlamydia).
The trials involved 216 women with viral sexually transmitted diseases: Cervical Dysplasia associated with papillomavirus infection (HPV) (Group 1); Herpes genitalis type 1 (HSV- 1) and type 2 (HSV-1) (Group 2); mixed infection - HSV-1, HSV-2 and chlamydia (Group 3).
Treatment results have confirmed that Proteflazid® contributes to sustainable performance improvement of basic factors of local immunity - sIgA, lysozyme and complement component C3 in the cervical mucus for all three groups of women.
Proteflazid® enhances level of local immunity markers (sIgA, lysozyme, C3 complement component) and improves their ratios. Also it intensifies anticontagious activity of mucosal protection and female reproductive system as whole, during treatment diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections (herpesvirus and chlamydia).
